Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Other Operating Expenses (2024 - 2025)

Kymera Therapeutics (KYMR) has disclosed Other Operating Expenses for 2 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • For Q3 2025, Other Operating Expenses changed N/A year-over-year to $3.9 million; the TTM value through Mar 2026 reached $3.9 million, changed N/A, while the annual FY2025 figure was $3.9 million, 21.73% down from the prior year.
  • Other Operating Expenses hit $3.9 million in Q3 2025 for Kymera Therapeutics, down from $4.9 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $4.9 million in Q1 2024 and bottomed at $3.9 million in Q3 2025.